116129-88-5

Basic information

• Product Name: (R)-2-BENZYL-SUCCINIC ACID 1-BENZYL ESTER 4-TERT-BUTYL ESTER
• Synonyms: (R)-2-BENZYL-SUCCINIC ACID 1-BENZYL ESTER 4-TERT-BUTYL ESTER;(R)-1-Benzyl 4-tert-butyl 2-benzylsuccinate
• CAS NO: 116129-88-5
• Molecular Formula: C₂₂H₂₆O₄
• Molecular Weight: 354.43944
• Mol File: 116129-88-5.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 460.9±33.0 °C(Predicted)
• Appearance: /
• Density: 1.099±0.06 g/cm3(Predicted)
• CAS DataBase Reference: (R)-2-BENZYL-SUCCINIC ACID 1-BENZYL ESTER 4-TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-BENZYL-SUCCINIC ACID 1-BENZYL ESTER 4-TERT-BUTYL ESTER(116129-88-5)
• EPA Substance Registry System: (R)-2-BENZYL-SUCCINIC ACID 1-BENZYL ESTER 4-TERT-BUTYL ESTER(116129-88-5)

Safety Data

• Hazardous Substances Data: 116129-88-5(Hazardous Substances Data)

Usage

General Description

(R)-2-benzyl-succinic acid 1-benzyl ester 4-tert-butyl ester is a chemical compound that is a combination of three different chemical groups. The (R)-2-benzyl-succinic acid group is a carboxylic acid compound, while the 1-benzyl ester group and the 4-tert-butyl ester group are both ester compounds. This chemical compound is often used in organic synthesis and as a building block for creating more complex chemical structures. Its unique combination of chemical groups gives it versatile reactivity and potential applications in various fields such as pharmaceuticals, materials science, and biochemistry.

Upstream product

• 136159-65-4 (S)-4-benzyl-3-(3-phenylpropanoyl)oxazolidin-2-one 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 116129-79-4 (4S)-3-<(2R)-2-<(tert-butyloxycarbonyl)methyl>-3-phenylpropionyl>-4-(2-propyl)oxazolidin-2-one 
• 100-51-6 benzyl alcohol 
• 150544-79-9 (4S)-3-<(2R)-2-<(tert-butyloxycarbonyl)methyl>-3-phenylpropionyl>-4-benzyloxazolidin-2-one 
• 645-45-4 hydrocinnamic acid chloride 
• 95798-31-5 (4S)-3-(3-phenylpropionyl)-4-(2-propyl)oxazolidin-2-one 

Downstream Products

• 122225-33-6 (2R)-3-tert-Butyloxycarbonyl-2-phenylmethylpropionic Acid 
• 122225-67-6 benzyl (2R)-2-benzyl-3-<(chloromethyl)carbonyl>propionate 
• 122225-29-0 Benzyl-(2R)-2 benzyl 3-(N-morpholino-carbamoyl)-propionate 
• 122225-70-1 Benzyl (2R)-2-Benzyl-5-tert-butylmercapto-4-oxopentanoate 
• 122225-75-6 benzyl (2R)-2-benzyl-5-morpholin-4-yl-4-oxopentanoate 
• 140926-08-5 (2S,3R,4S)-2-<-3-(4-thiazolyl)-L-alanyl>amino>-1-cyclohexyl-3,4-dihydroxy-6-methylheptane 
• 135683-92-0 N--(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6(2-pyridyl)-hexane-2-amide acetate 
• 135650-85-0 (2S,3R,4S)-N-piperidyl>carbonyl>propionyl>N^im-2-(2,4-dinitrophenyl)-L-histidinyl>-1-cyclohexyl-3,4-dihydroxy-6-(2-pyridyl)hexan-2-amine 
• 135631-93-5 (2S,3R,4S)-N-piperidyl>carbonyl>propionyl>-L-histidinyl>-1-cyclohexyl-3,4-dihydroxy-6-(2-pyridyl)hexan-2-amine 
• 135632-14-3 (1-{(R)-3-[(R)-1-((1S,2R,3S)-1-Cyclohexylmethyl-2,3-dihydroxy-5-pyridin-2-yl-pentylcarbamoyl)-2-methylsulfanyl-ethylcarbamoyl]-4-phenyl-butyryl}-piperidin-4-yl)-carbamic acid tert-butyl ester 
• 135632-41-6 (1-{(R)-3-[(S)-1-((1S,2R,3S)-1-Cyclohexylmethyl-2,3-dihydroxy-5-pyridin-2-yl-pentylcarbamoyl)-butylcarbamoyl]-4-phenyl-butyryl}-piperidin-4-yl)-carbamic acid tert-butyl ester 
• 135632-30-3 benzyl (2R)-3-<1-<<4-<(tert-butyloxycarbonyl)amino>piperidinyl>carbonyl>-2-benzyl>propionate 
• 135632-29-0 (2R)-3-<1-<<4-<(tert-butyloxycarbonyl)amino>piperidinyl>carbonyl>-2-benzyl>propionic acid 
• 114457-27-1 (R)-2-Benzyl-N-[(S)-1-((1S,2R,3S)-1-cyclohexylmethyl-2,3-dihydroxy-5-methyl-hexylcarbamoyl)-2-(1H-imidazol-4-yl)-ethyl]-4-morpholin-4-yl-4-oxo-butyramide 

Relevant articles and documents

Renin inhibitors containing a pyridyl amino diol derived C-terminus

Based on the concept of transition-state analogs, a series of nonpeptide renin inhibitors with the new (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy- 6-(2-pyridyl)hexane moiety at the C-terminal functionality were synthesized and evaluated for inhibition

Glaucoma treatment

A method and a composition for treating or reducing and/or controlling intraocular pressure comprising administering an effective amount of a renin inhibiting compound of the formula: STR1 where A is a substituent; W is CO or CHOH and U is CH2 or NR2 wherein R2 is hydrogen or loweralkyl; with the proviso that when W is CHOH then U is Ch2 ; R1 is loweralkyl, cycloalkyl methyl, benzyl, (alpha, alpha)-dimethylbenzyl, 4-hydroxybenzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, 1-bezyloxyethyl, phenethyl, phenoxy, thiophenoxy or anilino; R3 is loweralkyl, loweralkenyl, ((alkoxy)alkoxy)loweralkyl, (thioalkoxy)alkyl, benzyl or heterocyclic ring substituted methyl; and R4 is substituted hydroxyalkyamino.

Peptidyl difluorodiol renin inhibitors

A renin inhibiting compound of the formula: wherein A is a functional group; W is (1)-C(O)-,(2)-CH(OH)-or(3)-N(R?)-wherein R? is hydrogen or loweralkyl; U is (1)-C(O)-,(2)-CH?-or(3)-N(R?)-wherein R? is hydrogen or lower alkyl, with the proviso that when W is-CH(OH)-then U is-CH?-and with the proviso that U is-C(O)-or-CH?-when W is-N(R?)-; V is (1)-CH-,(2)-C(OH)-or(3)-C(halogen)-with the proviso that v is-CH--when U is-N(R?)-; Q is-CH(R?)-or-C(=CHR1a)-wherein R? is (1) loweralkyl,(2) cycloalkylalkyl,(3) arylalkyl,(4) (heterocyclic) alkyl,(5) 1-benzyloxyethyl,(6) phenoxy,(7) thiophenoxy or(8) anilino, provided that B is-CH?-or-CH(OH)-or A is hydrogen when R? is phenoxy, thiophenoxy or anilino and R1a is aryl or heterocyclic; R? is a functional group; R? is (1) loweralkyl,(2) cycloalkylmethyl or(3) benzyl; R? is-CH(OH)-or-C(O)-; R? is-CH(OH)-or-C(O)-; and Z is (1) lower alkyl,(2) aryl,(3) arylalkyl,(4) cycloalkyl,(5) cycloalkylalkyl,(6) heterocyclic or(7) (heterocyclic)alkyl; or a pharmaceutically acceptable salt, ester or prodrug thereof.